AMRX
Amneal Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Amneal Pharmaceuticals has 6 disclosed suppliers and 11 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputs8Q avg ±2.8%·×5.26·rich
straddle ±16.1%
spot 21.51exp Nov 20ATM strike 22.5ATM straddle 4.08IV 95%
−3.14%
vs ±15.6% implied · ×0.20
shaded = implied · ▲▼ = realized
SentenceThe following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2025 2024 2023 Customer A 25 % 23 % 24 %
basisAMRX FY2025 revenue $3.0B
AMRX 10-Kaccession 0001723128-26-000011
SentenceUnder the ApiJect Agreement, we will install and operate manufacturing equipment leased from Apiject at our Brookhaven, New York facility.
AMRX 10-Kaccession 0001723128-26-000011
SentenceONGENTYS ® is an add-on treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing "Off" episodes, which we commenced selling in early 2024 under a license agreement with BIAL-Portela & Ca., S.A.
AMRX 10-Kaccession 0001723128-25-000012
SentenceUNITHROID ® , indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.
AMRX 10-Kaccession 0001723128-25-000012
SentencePursuant to a development and supply agreement with Kashiv Biosciences LLC ("Kashiv") for a long-acting injectable, we paid Kashiv $10.0 million in February 2025 for the achievement of a regulatory milestone, which was accrued as of December 31, 2024.
AMRX 10-Kaccession 0001723128-25-000012
SentencePursuant to a licensing and supply agreement with mAbxience S.L. ("mAbxience") for two denosumab biosimilars referencing Prolia ® and XGEVA ® , the Company paid mAbxience $7.5 million in February 2026 upon the achievement of regulatory milestones.
AMRX 10-Kaccession 0001723128-26-000011
SentenceOn December 30, 2021, we entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, "Saol"), a private specialty pharmaceutical company, pursuant to which we agreed to acquire Saol's baclofen franchise, including Lioresal ® , LYVISPAH ™ , and a pipeline product under development (the "Saol Acquisition").
AMRX 10-Kaccession 0001723128-25-000012
SentenceOn May 8, 2025, the Company entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp. and related entities ("ApiJect"), a medical technology company focused on advanced drug delivery ("ApiJect Agreement").
AMRX 10-Kaccession 0001723128-26-000011
SentenceUNITHROID ® , indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.
AMRX 10-Kaccession 0001723128-25-000012
SentenceContingent upon Kashiv obtaining regulatory approval outside the U.S., we shall manufacture the commercial supply for Kashiv at a stated price.
AMRX 10-Kaccession 0001723128-25-000012
SentenceUpon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight.
AMRX 10-Kaccession 0001723128-25-000012
SentenceOur 2025 estimate includes capital expenditures for our collaboration and supply agreement with Metsera, of which we expect Metsera to reimburse us approximately $20.0 million.
AMRX 10-Kaccession 0001723128-25-000012
SentenceThe year-over-year decrease in net operating cash flows for the year ended December 31, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the year ended December 31, 2023 and (ii) receipt of a $21.4 million upfront payment associated with the license agreement with Orion Corporation during the year ended December 31, 2023, partially offset by (i) increased profitability adjusted for non-cash items, (ii) lower period over period payments associated with the Opana ER ® antitrust litigation settlement and (iii) favorable working capital movements, most notably an increase in days payables outstanding.
AMRX 10-Kaccession 0001723128-25-000012
SentenceOur AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
AMRX 10-Kaccession 0001723128-25-000012
SentenceOur AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
AMRX 10-Kaccession 0001723128-25-000012
SentenceOn December 19, 2025, the Company also entered into a distribution agreement with Valorum Oncology, LLC ("Valorum"), pursuant to which Valorum was appointed as Amneal's exclusive distributor of ALYMSYS ® in the territory (primarily the United States and Puerto Rico).
AMRX 10-Kaccession 0001723128-26-000011
SentenceUpon achieving regulatory approval for products, we will be responsible for manufacturing and supplying products to Zambon.
AMRX 10-Kaccession 0001723128-25-000012
Amneal Pharmaceuticals, Inc.
21.43